302 results about "Signal transduction" patented technology

Disclosed is a system for detecting whether the breast cancer is benign or malignant based on multiple modalities, which comprises: an ultrasonomics model configured to extract breast tumor position information and breast tumor morphological features on the basis of an acquired grayscale breast ultrasound image, perform global interactive fusion on the breast tumor position information and breast tumor morphological feature information, and convert a Transformer encoder-based feature output into an output vector of the corresponding classification dimensions by means of a fully connected layer; a metabonomics model configured to obtain a metabolic fingerprint spectrogram and analyze the metabolic fingerprint spectrogram on the basis of a metabolic database and a predetermined significantly differential metabolite to obtain abnormal metabolic pathways, signal transduction pathways, and related biochemical reactions associated with breast cancer malignancy; and a detection module configured to perform joint modeling, based on the breast tumor position information, the breast tumor morphological features, and a peak value of the significantly differential metabolite of the breast cancer malignancy, to output a prediction result about whether the breast cancer is benign or malignant.

The invention belongs to the technical field of protein, and relates to a peptide for promoting synthesis of a brain-derived neurotrophic factor (BDNF) as well as a preparation method and application of the peptide. The amino acid sequence of the peptide for promoting synthesis of the brain-derived neurotrophic factor BDNF is SGFSKHF, and the peptide has the main effects that damage of CORT (corticosterone) to PC12 cells can be protected, the peptide can be spontaneously combined with a TrkB receptor, the structure of a compound formed after combination is more stable, BDNF-TrkB-CREB pathway signal transduction can be activated, generation of the BDNF is promoted, and the effect of promoting synthesis of the brain-derived neurotrophic factor BDNF is achieved. Therefore, the occurrence and development of neurodegenerative diseases can be delayed.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

Methods for interfering or controlling IFN induction, IFN production and / or IFN activity are disclosed, harnessing viral mechanisms for evading or suppressing host anti-viral immune reactions. These methods comprise administration of one or more viral messenger RNAs (mRNAs) coding for proteins or peptides that control or interfere with signal transduction upstream and / or downstream of IFN induction, thereby providing a means for preventing or treating diseases, disorders or conditions associated with increased IFN production, such as cancer, autoimmune diseases, inflammatory diseases and interferonopathies.

The invention discloses a method for screening a Wilson disease serum exosome miRNA biomarker based on a transcriptomics technology, and belongs to the field of bioinformatics analysis of diseases. According to the invention, the effect of miRNA in WD pathogenesis is discussed by identifying serum exosome miRNA, and a potential biomarker is provided for accurate diagnosis and treatment of the disease. According to the invention, 59 DE-miRNAs are identified by analyzing the expression of differential miRNAs of WD and control group patients, and the DE-miRNAs are related to key approaches such as metabolic regulation, cancer progression, signal transduction and the like. Besides, the reliability of the key DE-miRNA, including miR-451a, miR-204-5p and the like, is confirmed through experimental verification, and the potential of the key DE-miRNA as a non-invasive biomarker is indicated. Research results provide important theoretical basis and new insight for accurate diagnosis of WD and development of potential therapeutic targets.

The invention discloses an antibody combined with interleukin 4 receptor (IL-4R) protein and a computer optimization method, a compound structure analysis method and application thereof, the antibody comprises a Fa-2 sequence, a Fa-3 sequence, a Fa-4 sequence, a Fa-5 sequence, a Fa-7 sequence, a Fa-13 sequence, a Fa-15 sequence, a Fa-16 sequence, a Fa-17 sequence, a Fa-19 sequence and a Fa-23 sequence, and the Fa-2 sequence, the Fa-3 sequence, the Fa-4 sequence, the Fa-5 sequence, the Fa-7 sequence, the Fa-13 sequence, the Fa-15 sequence, the Fa-16 sequence, the Fa-17 sequence, the Fa-19 sequence and the Fa-23 sequence comprise a heavy chain variable region and a light chain variable region. The amino acid sequences of the amino acid sequences are respectively shown as SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 29, 30, 33, 34, 35, 36, 37, 38, 41, 42, 49 and 50. According to the invention, a brand-new IL-4R epitope is found, and an antibody with a'non-ligand blocking 'characteristic is obtained for the first time. The invention opens up a brand new path for developing a therapy for intervening the IL-4R pathway through a new mechanism of regulating signal transduction or interacting with other coreceptors and the like, and is expected to overcome the limitation of the existing therapy. According to the method, computational biology and experimental structure biology are seamlessly connected, a set of repeatable and efficient research and development process is formed, and the method has a wide application prospect.

The invention provides a pathogen viable bacteria detection kit based on endogenous protein activated deoxyribozyme. The kit comprises a deoxyribozyme recognition element and a signal transduction element. The deoxyribozyme recognition element is composed of a substrate chain and an enzyme chain, and the signal transduction element is composed of two DNA reporter probes (Sub-F and Sub-Q), wherein the tail ends of the two DNA reporter probes are respectively marked with a fluorescence staining group and a fluorescence quenching group. The deoxyribozyme recognition element can recognize specific endogenous protein of target pathogenic viable bacteria and activate an enzyme chain to cut a substrate chain to generate two independent substrate chain fragments. And then a signal transduction element is introduced to realize specific output of a fluorescence signal. The kit provided by the invention can realize detection of living salmonella by targeting endogenous protein, can sensitively detect 190 CFU / mL of living salmonella with abundance as low as 0.1%, and has a good application prospect in the directions of food safety detection and clinical examination.

The invention belongs to the technical field of gene engineering, and particularly relates to application of a GhHAT18 gene in regulation and control of drought stress resistance of plants, the nucleotide sequence of the GhHAT18 gene is shown as SEQ ID NO.1. The invention discloses that the cotton histone acetylase gene GhHAT18 can be used for regulating and controlling the drought resistance of the plants for the first time, and experiments show that compared with a wild type plant, after the expression of the GhHAT18 gene is inhibited, the GhHAT18 gene can be used for regulating and controlling the drought stress resistance of the plants. The antioxidant enzyme activity and the drought resistance of plants can be obviously reduced; and the transgenic plant over-expressed with the GhHAT18 shows stronger and higher antioxidant enzyme activity and drought resistance under the drought stress. Transcriptome analysis shows that the GhHAT18 gene affects the expression of drought-resistant related genes through a secondary metabolite synthesis pathway and an MAPK signal transduction pathway, and the adaptive capacity of plants to drought stress is further regulated and controlled.

The invention relates to an anti-VEGF antibody, a heavy chain variable region sequence is shown as SEQ ID NO: 1, and a light chain variable region sequence is shown as SEQ ID NO: 2. According to the present invention, the monoclonal antibody capable of specifically binding to VEGF is prepared, the binding of VEGF and its receptor can be inhibited after the monoclonal antibody is bound to VEGF, the downstream signal transduction pathway of VEGF is blocked, and the animal test results show that the antibody can inhibit the growth of glioblastoma.

The invention discloses long-acting high-dynamic hydrazone bond hydrogel as well as a preparation method and application thereof, and particularly relates to the technical field of biomedical materials. The preparation method comprises the following steps: taking 1-adamantane acetic acid and adipic dihydrazide modified sodium hyaluronate and benzaldehyde-terminated eight-arm polyethylene glycol as carrier raw materials; the hydrazone bond hydrogel with relatively high stability is prepared through a coupling reaction of an aldehyde group of benzaldehyde-terminated eight-arm polyethylene glycol and a hydrazide group of 1-adamantane acetic acid and adipic dihydrazide modified sodium hyaluronate. The beta-cyclodextrin modified m-phenylenediamine catalyst is dynamically combined into the carrier through reversible host-guest complexation between beta-cyclodextrin and 1-adamantane acetic acid, so that the long-acting high-dynamic hydrazone bond hydrogel is obtained, and the requirement of three-dimensional culture of stem cells on mechanical properties can be met; and network dynamics can be maintained for a long time, so that stem cell spreading is supported, mechanical signal transduction is activated, osteogenesis-related gene expression is promoted, and stem cell osteogenesis differentiation capability is enhanced.

The invention discloses an MT (melatonin) and SNP (single nucleotide polymorphism) compound preservative as well as preparation and application thereof, and relates to the field of compound preservative films. A nitric oxide donor sodium nitroprusside (SNP); tween-80 (Tween-80) is added into auxiliary components to serve as an emulsifying agent, MT and SNP are dissolved in a proper amount of water and evenly stirred, then Tween-80 is added, and the MT and SNP compound preservative is prepared, according to the MT and SNP compound preservative and preparation and application thereof, MT and SNP are natural or quasi-natural components, compared with chemical preservatives, the MT and SNP have smaller potential harm to the environment and the human body, MT and SNP are used in a compound mode, and therefore the MT and SNP compound preservative has the beneficial effects that the MT and the SNP are more environmentally friendly and more environmentally friendly. MT and SNP cooperate with each other to improve the fresh-keeping effect, the antioxidant effect of MT can reduce oxidative damage in the fruits, SNP promotes endogenous NO generation, can regulate signal transduction in the fruits and further inhibits respiration and ethylene synthesis of the fruits, maturing and aging of the fruits are delayed from different angles through cooperation of MT and SNP, and the fresh-keeping effect of the fruits is improved. Meanwhile, the MT and the NO can cooperatively regulate and control signal transduction in the plant body, and the action time of the NO in the fruit body is prolonged.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.

The invention provides a chimeric antigen receptor for regulating and controlling a signal time sequence and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises a signal peptide, an extracellular domain, a transmembrane domain and an intracellular domain from an N terminal to a C terminal, the extracellular structural domain comprises an antigen recognition region and a hinge region; the intracellular domain comprises a costimulatory signal transduction region and a CD3 [zeta] intracellular region variant; the CD3 [zeta] intracellular region variant comprises three ITAMs, and the arrangement sequence of the ITAMs is ITAM3-ITAM2-ITAM1 from the N end to the C end. Compared with a conventional chimeric antigen receptor containing a wild CD3 zeta intracellular region, the chimeric antigen receptor provided by the invention can significantly enhance the functional activity of immune cells expressing the chimeric antigen receptor, which is specifically embodied in stronger multiplication capacity and durability, and significantly improves the antigen sensitivity and targeted killing efficacy.

This invention belongs to the field of biomedical technology, specifically relating to the application of DNA damage response gene-related SNPs in the treatment and prognosis of acute myeloid leukemia (AML). This invention is the first to discover that single nucleotide polymorphisms (SNPs) in the DNA damage response pathway (focusing on three major functional modules: damage sensing, signal transduction, and DNA repair) are closely related to the clinical characteristics, treatment response, and survival prognosis of AML. This lays the foundation for constructing a multi-gene risk model based on the DNA damage response pathway and provides theoretical support for integrating germline SNP maps into precision medicine strategies for AML.

The invention discloses an application of chloroquine in preparation of a medicine for treating glutamine deficiency type tumors, the chloroquine promotes IFN-gamma signal transduction by up-regulating IFNGR1 protein expression, so that the therapeutic effect of immunotherapy on the glutamine deficiency type tumors, ASCT2 low expression tumors or autophagy-lysosomal pathway active tumors is enhanced. The invention provides a new thought and an effective means for solving the problem of immunotherapy drug resistance caused by glutamine metabolism limitation, and has important theoretical significance and potential clinical application value.

Compounds and pharmaceutical compositions useful to treat cancer (e.g., lymphoma), neurodegenerative diseases, and autoimmune disorders include (1) a first nucleic acid sequence capable of binding to a transcription factor, for example, a signal transducer and activator of transcription (STAT) factor, such as STAT3, (2) a second nucleic acid sequence capable of binding a Toll-like receptor protein, for example, a CpG oligodeoxynucleotide, and (3) a ubiquitin ligase binding compound capable of binding a ubiquitin ligase protein, for example, a compound that is capable of binding a cereblon protein, such as lenalidomide, pomalidomide, or thalidomide.

The invention discloses a detection kit based on orthogonal dual-channel label-free CRISPR-Cas and application of the detection kit, relates to the technical field of nucleic acid detection, and constructs an orthogonal dual-channel response system by utilizing the differentiated cleavage activity of Cas12a targeted DNA and Cas13 targeted RNA to a substrate. A Cas12a pathway is reported by utilizing protoporphyrin IX to be compounded with G-quadruplex G4DNA, and a Cas13a pathway is reported by utilizing DFHBI to be compounded with a Broccoli RNA structure, so that label-free signal transduction is realized. Through accurate screening of fluorophores, channel specificity is ensured, and optical signal crosstalk is eliminated. Mycobacterium tuberculosis (MTB) and respiratory syncytial virus (RSV) are used as model pathogens for verification, and a multiple recombinase polymerase amplification (RPA) technology is combined, so that the detection sensitivity on a synthetic target reaches a single molecule level. The system has high specificity, and even if the concentration of a non-target pathogen is increased by 100 times, no cross reaction exists.

The present application relates to a kind of based on logic gate double-target point chimeric antigen receptor modified TIL cell, lentivirus expression vector and application, belong to tumor immunotherapy and gene editing technical field.The TIL cell based on logic gate double-target point chimeric antigen receptor modified in the application, double-target point chimeric antigen receptor includes chimeric antigen receptor EGFR and chimeric antigen receptor GD2;Chimeric antigen receptor EGFR is composed of CD8 alpha signal peptide, anti-EGFR single-chain antibody, CD8 alpha transmembrane region, 4-1BB costimulatory domain and CD3 zeta intracellular signal domain in series;Chimeric antigen receptor GD2 is composed of CD8 alpha signal peptide, anti-GD2 single-chain antibody, CD28 transmembrane region, CD27 costimulatory domain and CD3 zeta intracellular signal domain in series.The present application solves the defects that lentivirus transduction targeting is poor in prior art, CAR signal activation specificity is insufficient, TIL cell is easily exhausted, has the advantages that gene integration is accurate, signal transduction is controllable, in-vivo survival time is long, can be efficiently used for the immunotherapy of double-antigen co-expression solid tumor.

The present application belongs to the technical field of fruit fly prevention and control, and discloses a disorienting agent, a preparation method and application thereof. The disorienting agent contains rosemary extract and orange peel essential oil. The rosemary extract and orange peel essential oil contain terpenes and other compounds (such as 1,8-cineole in rosemary), which can compete with natural signal molecules to bind to odor binding proteins or olfactory receptors, which can cause fruit flies to fail to activate the correct nerve signal or directly block the signal transduction pathway. The orange peel essential oil in the disorienting agent has a strong smell, which can strongly cover or mask the weak smell signal emitted by the fruit, forming an "olfactory masking" effect, so that the fruit fly cannot find the fruit. Moreover, compared with sex pheromones as disorienting agents, which can only act on male fruit flies, the disorienting agent of the present application can interfere with the olfactory receptors of adult fruit flies to make them unable to find the target, so that they cannot accurately locate the oviposition site and harm the fruit. The disorienting agent is effective for both female and male fruit flies.

Compounds having the following formula I:or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and / or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

The invention discloses a method for improving rooting quality of eucommia ulmoides by regulating ethylene, and relates to the technical field of eucommia ulmoides breeding. The method comprises the following steps: selecting eucommia ulmoides tissue culture clonal elongation buds as a material; inoculating the elongated buds into an adventitious root one-step induction (O treatment) culture medium; in addition, performing two-step rooting induction (T treatment) on the elongated buds: pre-culturing for 7 days, and then transferring into a hormone-free culture medium; differential genes of an ethylene signal transduction pathway and a biosynthesis pathway on the twelfth day and the twenty-first day of O treatment and T treatment are analyzed, and it is determined that ethylene may be a main factor affecting the two rooting modes; the mutual regulation effect of NAA and ethylene is further verified, and the development of adventitious roots of eucommia ulmoides is regulated by indirectly regulating the generation of ethylene. The method has the beneficial effects that the efficient eucommia ulmoides rooting method which is high in rooting efficiency, robust in root system, few in callus formation and clear in mechanism is developed, and the method has important significance in research on promoting adventitious root development of eucommia ulmoides.

The invention relates to the field of information systems and cloud platforms for interaction detection of proteins and metabolites and health correlation in biological material test and analysis, and discloses a short figure development multi-dimensional data fusion evaluation system based on an intestinal brain liver axis quantitative model. Comprising a data acquisition module, an axial gating mapping module and a growth steady state evaluation module, and the data acquisition module acquires an intestinal metabolism component, a liver growth axis component and a neuroendocrine component of a subject; the axial gating mapping module is used for determining signal transduction time delay, calling an intestinal metabolism component at the T-tau moment as a parameter reference through asynchronous offset processing, and determining a gating calibration coefficient in combination with a neuroendocrine component fluctuation slope; and the growth steady state evaluation module performs gain compensation on the liver growth axis component according to the calibration coefficient and outputs a growth and development evaluation index. According to the invention, asynchronous interference of biochemical signal circulation is solved, evaluation model drift caused by phase dislocation is eliminated, and the accuracy of development blocking reason screening is enhanced.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The invention relates to the technical field of adoptive immunotherapy, in particular to a double-target CD19 / CD79b CAR structure and application thereof. The structure comprises a Loop CAR structure or a tan CAR structure, and the Loop CAR structure or the tan CAR structure comprises a signal peptide sequence, an antigen binding structural domain, a connecting peptide, an antigen binding structural domain, a hinge region, a transmembrane structural domain, a costimulatory signal molecule and a cytoplasm signal transduction sequence which are connected in sequence; the antigen binding structural domain is an independent scFV structure aiming at specific targets, and the specific targets comprise CD19 and CD79b. The structure can be applied to immune cells, nucleic acid molecules and carriers. The structure can improve the killing effect.

The present disclosure provides compositions and methods for inducing protein-protein heterodimerization in the presence of salicylic acid or a synthetic derivative thereof, useful for modulating signal transduction, protein activation, and gene expression in response to chemical stimuli.

The invention discloses a composite exosome encapsulating linear macromolecular nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of biological materials and regenerative medicine. Aiming at the pain points that in the prior art, when linear macromolecules such as collagen and hyaluronic acid are encapsulated by exosomes, the encapsulation efficiency is low, the structure of the exosomes is easy to damage, and the molecular weight adaptability is poor, the invention provides the preparation method which comprises the following steps: firstly, pretreating the collagen of 5 kDa to 330 kDa and the hyaluronic acid of 10 kDa to 2200 kDa into dense nanoparticles of 10 to 150 nm and PDI less than or equal to 0.15 through a nanoprecipitation method, an electrostatic complexation method and the like; and encapsulating in the exosome through an electroporation method, a freeze-thaw cycle method or an ultrasonic method, and purifying to obtain the composite exosome. According to the method, linear macromolecules with different molecular weights are adapted by flexibly adjusting process parameters, the encapsulation efficiency is remarkably improved, and the membrane structure of the exosome can be kept complete. The obtained composite exosome has the signal transduction function of the exosome and the biological activity of linear macromolecules, and generates a synergistic effect in tissue repair.

The invention discloses application of a tomato gene SlZFP2 as a negative regulation factor in regulation of plant cold resistance, belongs to the technical field of plant genetic engineering, and finds and confirms that the tomato zinc finger protein gene SlZFP2 is a key negative regulation factor of plant cold resistance for the first time. Experiments show that the expression of the SlZFP2 is induced by low temperature, the overexpressed transgenic tomato plant shows more serious cold injury symptoms under low temperature stress, the photosynthetic efficiency is reduced, active oxygen (H2O2 and O2-) is excessively accumulated, and the activity of antioxidant enzymes (SOD, POD and CAT) is weakened; the overexpression of the SlZFP2 can inhibit the biosynthesis and signal transduction of abscisic acid (ABA), and down-regulate the expression of cold response genes SlGRAS4 and SlCBF1; based on the discovery, the invention provides an application of using the SlZFP2 gene or an expression product thereof as a molecular marker for screening tomato materials with different cold resistance, creating a transgenic plant with reduced cold resistance by overexpressing the SlZFP2, and providing a recombinant DNA construct containing an SlZFP2 coding sequence and a host cell.

The present disclosure relates to compounds and methods useful for the modulation of signal transducer and activator of transcription 6 ("STAT6") via ubiquitination and / or degradation by compounds according to the present disclosure. The present disclosure also provides pharmaceutically acceptable compositions thereof and methods of using said compositions in the treatment of various disorders.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.